Didn't they outlicense it to an Asian (Singaporean?) company, or am I thinking of something else?
You're thinking of ARRY-543, the HER2/EGFR inhibitor, that was licensed to ASLAN (#msg-65133150 ). Tony is referring to ARRY-380, which actually did have some limited PoC in breast cancer patients (#msg-55080837 ) and is still available for partnering. ARRY doesn't give a ton of buzz on partnering talks for the drug, though they did disclose in the 4Q11 CC in August that they hoped to culminate a deal for the drug in the coming quarters (#msg-66030567 ). Would be nice if they got a nice up-front for this drug as they could use the cash.
Market Data 
Markets 
AI
